Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883696 | 0.87 | CYP3A4 (0.73) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL12926432 | 0.87 | CSF1R (0.71) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1267493 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1267417 | 0.85 | CYP3A4 (0.77) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL12898164 | 0.84 | CYP3A4 (0.69) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1266685 | 0.84 | CYP1A2 (0.67) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1884529 | 0.83 | CYP3A4 (0.63) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1266963 | 0.82 | CYP3A4 (0.74) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL1889713 | 0.81 | CYP3A4 (0.76) | CYP3A4CYP2C19CYP2C9KITCSF1R | |
| SCHEMBL4518117 | 0.78 | CYP3A4 (0.72) | CYP3A4CYP2C19CYP2C9KITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP3A4 3847/4885CYP2C19 3327/4885CYP2C9 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.